Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Some Current Issues in the Management of Prostate Cancer Suman Chatterjee MD Active Surveillance ● ● Concept: A certain subset of prostate cancer is slow growing Goals: – Delay the toxic side effects of definitive treatment – Have equivalent success in outcome vs immediate treatment Active Surveillance ● Vs. Watchfull waiting – An older paradigm – Slow nature of progression of prostate cancer would only necessitate treatment after years – In the interval other comorbidities would impact the patients life expectancy Active Surveilance ● The “ideal” candidate – Healthy male able to undergoe definitive treatment – Clinically confirmed INDOLENT disease – Willing and interested in continued close observation and monitoring (including repeat biopsy) Active Surveillance ● INDOLENT DISEASE – Initially defined by Epstein as ● ● ● – Gleason 3+3 disease <3 cores + < 50% of any one core This “classic” definition is now being expanded although our understanding of this is still limited. Active Surveillance Active Surveillance ● Important Points: – To date 7 large series are available – Longest median followup is 6.8 years – PCa mortality is <1% – ~30% progress to definitive therapy – Median time to “progression” is 2.5 years Active Surveilance Active Surveillance Androgen Deprivation Therapy ● Rationale – Prostate cancer was the first solid organ malignancy which was shown to be influenced by endogenous hormones – Removing the supply of testosterone “inactivates” the growing prostate cancer tumor for a period of time – Invariably the effects of androgen deprivation are countered by the tumor as it becomes refractory. Androgen Deprivation Androgen Deprivation ● Effects: – Dramatic reduction in PSA and Testosterone levels – Within 28 days most men will have become castrate – By 3 months radiologic progression of the tumor is halted Androgen Deprivation ● Durability – This is dependent on the pathology of the original tumor – Studies seem to indicate as an average 3-5 years of good PSA (ie tumor) control followed by another 1-2 years where the tumor progresses but symptoms are minimal – Clinically response is quite varied. Androgen Deprivation ● Uses: – Local Disease ● ● ● Improved survival and control in men treated with XRBT in combination with LHRH agonists Occasionally in order to facilitate brachytherapy in men with large prostates GENERALLY NOT USED WITH SURGERY – Studies did not identify a benefit Androgen Deprivation ● Uses: – Metastatic Disease: ● ● ● Still considered first line therapy Currently intermittent therapy and continous therapy are used depending on pathology In patients with castrate resistant disease androgen deprivation is still given as a subset of the tumor will still show response Androgen Deprivation ● Side Effects: – These are divided as short and long term – Short term: ● ● ● ● Hot flashes Mood/ energy effects Weight gain Loss of libido/ ED Androgen Deprivation ● Side effects: – Long term: ● ● ● ● Loss of bone mineral density Altered lipid profile Increased Cardio Vascular Events Memory/ Cognitive effects Androgen Deprivation ● Prevention – Vit D & Ca supplementation – Weight bearing exercise – Healthy diet – Baseline BMD at 1 year post treatment 5ARI's and Prostate Cancer 5 Alpha Reductase Inhibitors include: Proscar (Finasteride) Avodart (Dutasteride) 5 ARIs and Prostate Cancer ● ● ● 2 Large studies (PCPT and REDUCE) have shown that low risk prostate cancer is prevented with the daily use of 5ARI's over extended periods The relative risk reduction in both is about 25% There also appears to be an absolute 1.3% increase in the detection of high grade disease 5ARI's and Prostate Cancer ● Why is this? – It's generally not “biologically plausable” that a treatment that slows one subset of a disease increases the risk of a more advanced subset of the same disease – As we currently understand it gleason 6 disease and gleason 8 disease are variations of the same entity so they should react the same way 5ARI's and Prostate Cancer ● Explanations: – Sampling 5ARI's and Prostate Cancer ● Other explanations: – Delay in progression – Pathologic Attributes – Induction Thank you